LECIP-ARCONTIA
9.12.2020 10:02:07 CET | Business Wire | Press release
A modern standard device for e-ticketing – the EMV Level 2 Certified LECIP Validator “LV-700” provides public transport authorities with great access to contactless ticketing. The state-of-the-art validator is compliant with VDV-KA and a great enhancement to the end-to-end ticketing solutions from the IVU.suite. LECIP Arcontia AB has agreed to supply IVU Traffic Technologies AG with the LV-700 validator as an integrated part of their IVU.suite product line-up.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005021/en/
LECIP ARCONTIA AB and IVU Traffic Technologies AG have concluded a non-exclusive partnership on the distribution of LECIP’s on-board validator “LV-700” which IVU will offer as part of their integrated, one-stop solution IVU.suite. Being EMV L1/L2 compliant, LV-700 will provide a wide variety of payment solutions as an important device of contactless ticketing solutions.
The LV-700 series is designed for fast and smooth cashless and contactless payment with a high-speed processor and large capacity memory for demanding ticket data processing. Contactless payment by using credit cards has become very popular around the globe, preventing crimes such as skimming, and making payment more convenient and secure.
Within the IVU.suite, the IVU.validator-branded LV-700 will play an important role supporting the end-to-end ticketing solutions IVU.fare and IVU.ticket as well as the driver operated on-board computer IVU.ticket.box. By enabling the customers to make quick and uncomplicated cashless payments, the IVU.validator takes some of the pressure from the driver and makes boarding faster.
“As we are migrating our platform to Linux we are excited to be partnering with LECIP Arcontia and start implementing their LV-700 in our upcoming projects,” says Henrik Benner, Head of Equipment Development at IVU Traffic Technologies AG. “Thanks to its VDV-KA compliance and its future proof technology, the validator is a great tool for a more contactless future, and we are looking forward to introducing it to our customers.”
LECIP ARCONTIA AB, a subsidiary of LECIP HOLDINGS CORPORATION (TOKYO: 7213) of Gifu, Japan, operates globally to deliver contactless smart card products and solutions for Automated Fare Collection System (AFC). We develop and distribute smart card readers and terminals used in over 40 countries. Our focus is to deliver reliable, high quality contactless smart card products, and implement software services featuring the latest technology and market requirements in e-ticketing and payment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release
Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic
An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom